No eGFR Cut-off Required for Bilastine
Bilastine does not require dose adjustment based on eGFR and can be safely administered at the standard 20 mg daily dose across all degrees of renal insufficiency, including severe renal impairment (eGFR ≤30 mL/min/1.73 m²).
Evidence Base
The pharmacokinetic study of bilastine in renal insufficiency 1 provides the definitive answer to this question. This study evaluated bilastine 20 mg in patients stratified by renal function:
- Healthy subjects (GFR >80 mL/min/1.73 m²)
- Mild renal insufficiency (GFR 50-80 mL/min/1.73 m²)
- Moderate renal insufficiency (GFR 30-50 mL/min/1.73 m²)
- Severe renal insufficiency (GFR ≤30 mL/min/1.73 m²)
Key Findings
While bilastine exposure (AUC) increased progressively with worsening renal function—ranging from 737.4 ng·h/mL in healthy subjects to 1708.5 ng·h/mL in severely impaired subjects—the increased exposure remained well within established safety margins 1. The study concluded that a 20 mg daily dose can be safely administered without dose adjustments across all degrees of renal insufficiency.
Clinical Reasoning
Bilastine is primarily eliminated renally, with renal clearance paralleling GFR 1. Despite this renal-dependent elimination, the drug demonstrated:
- Excellent tolerability across all renal function groups
- No alternative elimination pathways activated even in severe renal insufficiency
- Maintained safety profile despite approximately 2.3-fold increase in exposure from normal to severe renal impairment
The oral plasma clearance to renal clearance ratio remained approximately equal across all groups, confirming renal excretion as the main elimination route without compensatory mechanisms 1.
Practical Application
For prescribing bilastine:
- Standard dose: 20 mg once daily for all patients
- No monitoring required for renal function specifically related to bilastine dosing
- No contraindications based on eGFR level
- Safe in dialysis patients (though specific dialysis data not provided, severe renal insufficiency data supports safety)
Important Caveat
This recommendation applies specifically to bilastine, a second-generation antihistamine. The evidence provided about other medications (diabetes drugs, etc.) in the search results is not relevant to bilastine dosing and should be disregarded for this specific question.